Catalent, Inc. Common Stock (CTLT)
Frequently Asked Questions About Catalent, Inc. Common Stock (CTLT)
How does Catalent contribute to the fight against COVID-19?
Catalent has played a significant role in the fight against COVID-19 by providing essential manufacturing services for vaccines and therapeutics. The company has leveraged its facilities and expertise to support the rapid production of critical products, working collaboratively with partners to ensure timely delivery and distribution during the pandemic.
How does Catalent foster partnerships with clients?
Catalent fosters partnerships with clients through collaborative approaches that prioritize open communication and shared goals. The company works closely with clients to understand their needs and challenges, providing tailored solutions and expert guidance throughout the drug development process to ensure successful outcomes.
How does Catalent support innovation in drug development?
Catalent actively supports innovation in drug development through its extensive range of services and advanced technologies. The company collaborates with clients to create customized solutions that enhance drug delivery, stabilize formulations, and optimize production processes. Moreover, Catalent invests in research and development to stay at the forefront of industry advancements.
How many employees does Catalent have?
As of the most recent data, Catalent employs approximately 14,000 individuals across its global operations. The company's workforce includes a diverse team of professionals with expertise in various fields, including engineering, quality assurance, regulatory affairs, and manufacturing, all dedicated to supporting its clients in the life sciences sector.
Is Catalent a publicly traded company?
Yes, Catalent, Inc. is publicly traded and is listed on the New York Stock Exchange under the ticker symbol CTLT. The company became publicly listed in 2014, providing investors the opportunity to participate in its growth and development in the healthcare sector.
What are the main services offered by Catalent?
Catalent offers a comprehensive range of services, including drug formulation development, clinical and commercial manufacturing, packaging, and supply chain solutions. Its specialized capabilities also extend to clinical trial materials, analytical testing, and advanced delivery technologies, all aimed at ensuring the success of pharmaceutical products from conception to market launch.
What does Catalent, Inc. do?
Catalent, Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. The company specializes in providing a variety of services, including formulation development, analytical services, and production for pharmaceuticals, biotechnology, and nutraceuticals. Catalent aims to enhance the efficiency of the drug development process and ensure the reliability of the products reaching the market.
What is Catalent's focus on quality?
Quality is a cornerstone of Catalent's operations, as the company is dedicated to meeting stringent industry standards and ensuring product integrity. Catalent adheres to Good Manufacturing Practices (GMP) and employs rigorous testing and quality assurance protocols throughout its manufacturing processes to maintain high-quality outcomes for its clients’ products.
What is Catalent's stance on research and development?
Catalent places a strong emphasis on research and development (R&D) as a means of driving innovation in drug delivery and manufacturing solutions. The company invests in R&D initiatives to advance its technologies and capabilities, enabling it to offer clients the latest solutions and methodologies to enhance the development and commercialization of their products.
What is Catalent’s approach to sustainability?
Catalent is committed to incorporating sustainability practices into its operations by focusing on reducing its environmental footprint and promoting responsible resource usage. The company invests in energy-efficient technologies, waste reduction efforts, and initiatives aimed at compliance with environmental regulations to contribute positively to the communities where it operates.
What is the significance of softgel manufacturing for Catalent?
Softgel manufacturing is a significant aspect of Catalent's operations, as it is a leading provider of softgel capsules worldwide. This dosage form offers unique advantages, such as improved bioavailability, dose accuracy, and enhanced patient compliance. Catalent's expertise in this area allows it to serve a variety of clients looking to develop innovative softgel formulations.
What markets does Catalent serve?
Catalent serves a wide array of markets within the life sciences sector, including pharmaceuticals, biotechnology, and consumer health. The company is involved in various therapeutic areas, such as oncology, cardiovascular health, and infectious diseases, allowing it to meet the diverse needs of its customers.
What recent acquisitions has Catalent made?
Catalent has made several strategic acquisitions to enhance its service capabilities and market position. Notable recent acquisitions include the purchase of Maestrani Chocolatier, which expanded its capabilities in the field of cannabis and additional therapeutic delivery systems, as well as other companies focused on advanced drug delivery technologies and biologics manufacturing.
What role does Catalent play in clinical trials?
Catalent plays a crucial role in clinical trials by providing comprehensive support services, including the production of clinical trial materials, supply chain management, and analytical testing. The company's expertise in drug formulation and delivery helps ensure that trials are conducted efficiently and that investigational products maintain quality and integrity throughout the process.
What types of products does Catalent produce?
Catalent produces a diverse range of products that include prescription and over-the-counter medications, biologics, and consumer health products. Their offerings also encompass advanced delivery technologies such as softgel capsules, oral solids, and injectables, catering to the unique needs of their clients across various therapeutic areas.
When was Catalent, Inc. founded?
Catalent, Inc. was founded in the year 2007, but it has roots dating back to the 1970s when it began as part of the Cardinal Health company. Over the years, it has evolved into a standalone organization focusing exclusively on delivering innovative solutions for the pharmaceutical and biotechnology industries.
Where are Catalent's manufacturing facilities located?
Catalent operates multiple manufacturing facilities around the globe, including locations in the United States, Europe, and Asia. These facilities are strategically situated to ensure efficient production, logistics, and compliance with international regulatory standards, enabling Catalent to serve clients effectively on a worldwide scale.
Where is Catalent, Inc. headquartered?
Catalent, Inc. is headquartered in Somerset, New Jersey, USA. This strategic location allows the company to be in proximity to important pharmaceutical markets and provides convenient access to clients and partners in the life sciences sector.
Who are the key competitors of Catalent?
Catalent faces competition from several prominent companies in the pharmaceutical and biopharmaceutical contract manufacturing space. Key competitors include Lonza Group AG, Parexel International Corporation, and Famar Health Care Services, among others. These companies offer similar services in drug development, manufacturing, and delivery solutions.
What is the current price of Catalent, Inc. Common Stock?
The current price of Catalent, Inc. Common Stock is 63.48
When was Catalent, Inc. Common Stock last traded?
The last trade of Catalent, Inc. Common Stock was at 7:00 pm EST on December 17th, 2024
What is the market capitalization of Catalent, Inc. Common Stock?
The market capitalization of Catalent, Inc. Common Stock is 10.81B
How many shares of Catalent, Inc. Common Stock are outstanding?
Catalent, Inc. Common Stock has 170.34M shares outstanding.